The stock of Novo Resources Corp (CVE:NVO) is a huge mover today! About 15,750 shares traded hands. Novo Resources Corp (CVE:NVO) has risen 6.00% since September 17, 2016 and is uptrending. It has outperformed by 0.39% the S&P500.
The move comes after 6 months positive chart setup for the $124.63M company. It was reported on Oct, 17 by Barchart.com. We have $3.23 PT which if reached, will make CVE:NVO worth $143.32M more.
More notable recent Novo Resources Corp (CVE:NVO) news were published by: Juniorminingnetwork.com which released: “Novo Resources To Purchase Previously-Optioned Projects From Talga Resources” on August 25, 2016, also Juniorminingnetwork.com with their article: “Sampling Returns High Grades at Novo Resources Blue Spec Gold-Antimony Project” published on January 21, 2016, Juniorminingnetwork.com published: “Novo Mining Receives Trial Processing Approvals” on August 10, 2016. More interesting news about Novo Resources Corp (CVE:NVO) were released by: Juniorminingnetwork.com and their article: “Novo Mining Commences Bulk Sample at Beatons Creek Gold Project” published on July 29, 2016 as well as Juniorminingnetwork.com‘s news article titled: “Novo Plans Aggressive Drilling Along The Blue Spec Shear Zone” with publication date: June 23, 2016.
Novo Resources Corp. is engaged in the business of evaluating, acquiring and exploring natural resource properties. The company has a market cap of $124.63 million. The Company’s exploration and evaluation assets include Beatons Creek, Grant’s Hill, PaleoPlacer, Tuscarora, Blue Spec, Talga, Two Creeks and Mt. It currently has negative earnings. Hayes.
NVO Company Profile
Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.